The Role of Sildenafil towards Health Related Quality of Life in Adults with Pulmonary Arterial Hypertension Related Uncorrected Secundum Atrial Septal Defect

Author : F. Hidayati*, P.P.R. Gharini*, A.B. Hartopo*, D.W. Anggrahini*, L.K. Dinarti*
Upload Date : 19-04-2018

Background: Pulmonary arterial hypertension (PAH) is a common complication of atrial septal defect (ASD). Assessment of health-related quality of life (HRQoL) are often measured as an important patient-reported outcome in clinical studies. This study aimed to assess the HRQoL of PAH related uncorrected secundum ASD with oral sildenafil therapy.

Methods: Adults with PAH related uncorrected secundum ASD (n=18) received oral sildenafil (20 mg two or three times daily) during 12 weeks in quasi experimental study at Sardjito Hospital Yogyakarta since April 2016 to August 2017. HRQoL data were obtained using  EQ-5D-3L questionnaire at baseline and 12 weeks after therapy. The differences of EQ-5D utility and EQ-VAS score were analyzed using paired T-test.

Results: The most frequent reported problems pre therapy were pain/discomfort (83%) and anxiety/depression (78%). The mean value of EQ-5D utility score was 0.558 while 0.664 post therapy (p:0.014; 95% CI 0.024-0.187). Whereas, the mean value of EQ-VAS score pre and post therapy was 65 and 71.67, respectively (p:0.005; 95% CI 2.32-11.02). Mild side effects were experienced by 11.11% subjects.

Conclusion: Oral sildenafil for 12 weeks statistically significant improves HRQoL in adult with PAH related uncorrected secundum ASD.

KEYWORDS : health related quality of life, pulmonary arterial hypertension, atrial septal defect, sildenafil

Copyrights 2018 ASMIHA | Managed by Indonesia Medical Event (IME)